Similar articles

• Chronic hepatitis C virus infection.

  Flamm SL. Flamm SL. JAMA. 2003 May 14;289(18):2413-7. doi: 10.1001/jama.289.18.2413. JAMA. 2003. PMID: 12746366 Review. No abstract available.
• [Therapy of chronic hepatitis C].

  Schaffstein S, Rampini SK, Müllhaupt B. Schaffstein S, et al. Praxis (Bern 1994). 2014 Apr 9;103(8):423-36. doi: 10.1024/1661-8157/a001618. Praxis (Bern 1994). 2014. PMID: 24713377 Review. German. No abstract available.
• Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.

  Bader el-Din NG, Abd el-Meguid M, Tabll AA, Anany MA, Esmat G, Zayed N, Helmy A, el-Zayady AR, Barakat A, el-Awady MK. Bader el-Din NG, et al. J Gastroenterol Hepatol. 2011 Jan;26(1):55-62. doi: 10.1111/j.1440-1746.2010.06319.x. J Gastroenterol Hepatol. 2011. PMID: 21175794
• [Treatment for chronic hepatitis C, more opportunity, more challenge].

  Wei L. Wei L. Zhonghua Gan Zang Bing Za Zhi. 2009 Jul;17(7):481-3. Zhonghua Gan Zang Bing Za Zhi. 2009. PMID: 19912676 Chinese. No abstract available.
• Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.

  Ferraro D, Bonura C, Giglio M, Di Stefano R, Almasio PL, Di Marco V, Craxì A, Cacciola I, Squadrito G, Raimondo G. Ferraro D, et al. J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):172-5. J Biol Regul Homeost Agents. 2003. PMID: 14518718 Clinical Trial.